Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005103 · ClinicalTrials.gov registry record
Study of the Pathogenesis of Porphyria Cutanea Tarda
A clinical trial of Porphyria Cutanea Tarda, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT00005103: Completed study of Porphyria Cutanea Tarda, sponsored by National Center for Research Resources (NCRR).
NCT00005103 is a study of Porphyria Cutanea Tarda that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005103, a study of Porphyria Cutanea Tarda, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Determine the effect of standard treatments on various predisposing factors in patients with porphyria cutanea tarda (PCT). II. Investigate alcohol history, smoking, liver dysfunction and its etiology, estrogen use, and family history of PCT in these patients. III. Study the relationships of excess iron and the hemochromatosis gene to PCT, including clinical features and risk of recurrence in these patients. IV. Assess hepatitis C virus infections in these patients. V. Assess vitamin C levels in these patients before and after treatment. VI. Assess dietary habits in these patients. VII. Assess activity of cytochrome P450 enzymes (CYP) in vivo in these patients. VIII. Study polymorphic genes for enzymes that metabolize foreign chemicals, including CYP enzymes and glutathione transferases in these patients.
Conditions Studied
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2000-11 |
What the finished NCT00005103 record still lists
NCT00005103 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Porphyria Cutanea Tarda appearing as the primary indexed condition, and to 0 interventions.
NCT00005103 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00005103 about?
NCT00005103 is a clinical study titled "Study of the Pathogenesis of Porphyria Cutanea Tarda". OBJECTIVES: I. Determine the effect of standard treatments on various predisposing factors in patients with porphyria cutanea tarda (PCT). II. Investigate alcohol history, smoking, liver dysfunction and its etiology, estrogen use, and family history of PCT in these patients. III. Study the relatio...
What is the current status of trial NCT00005103?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2000-11.
What conditions does trial NCT00005103 study?
This clinical trial studies the following conditions: Porphyria Cutanea Tarda.
Who is sponsoring clinical trial NCT00005103?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005103 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Porphyria Cutanea Tarda
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia